Show simple item record

dc.contributor.authorWoo, K.
dc.contributor.authorStewart, S.
dc.contributor.authorKong, G.
dc.contributor.authorFinch-Edmondson, M.
dc.contributor.authorDwyer, B.
dc.contributor.authorYeung, S.
dc.contributor.authorAbraham, L.
dc.contributor.authorKampmann, S.
dc.contributor.authorDiepeveen, L.
dc.contributor.authorPassman, A.
dc.contributor.authorElsegood, Caryn
dc.contributor.authorTirnitz-Parker, Nina
dc.contributor.authorCallus, B.
dc.contributor.authorOlynyk, J.
dc.contributor.authorYeoh, G.
dc.date.accessioned2017-01-30T13:11:35Z
dc.date.available2017-01-30T13:11:35Z
dc.date.created2016-07-13T19:30:16Z
dc.date.issued2016
dc.identifier.citationWoo, K. and Stewart, S. and Kong, G. and Finch-Edmondson, M. and Dwyer, B. and Yeung, S. and Abraham, L. et al. 2016. Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib. European Journal of Medicinal Chemistry. 120: pp. 275-283.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/29259
dc.identifier.doi10.1016/j.ejmech.2016.03.015
dc.description.abstract

© 2016 Elsevier Masson SASBackground & aims The availability of non-tumorigenic and tumorigenic liver progenitor cell (LPC) lines affords a method to screen putative anti-liver cancer agents to identify those that are selectively effective. To prove this principle we tested thalidomide and a range of its derivatives and compared them to lenalidomide and sorafenib, to assess their growth-inhibitory effects. Methods Cell growth, the mitotic and apoptotic index of cell cultures were measured using the Cellavista instrument (SynenTec) using commercially available reagents. Results Neither lenalidomide nor thalidomide (100 µM) affected tumorigenic LPCs but killed their non-tumorigenic counterparts. Sorafenib arrested growth in both cell types. All but two derivatives of thalidomide were ineffective; of the two effective derivatives, one (thalidomide C1) specifically affected the tumorigenic cell line (10 µM). Mitotic and apoptotic analyses revealed that thalidomide C1 induced apoptotic cell death and not mitotic arrest. Conclusions This study shows that screens incorporating non-tumorigenic and tumorigenic liver cell lines are a sound approach to identify agents that are effective and selective. A high throughput instrument such as the Cellavista affords robust and reproducible objective measurements with a large number of replicates that are reliable. These experiments show that neither lenalidomide nor thalidomide are potentially useful for anti-liver cancer therapy as they kill non-tumorigenic liver cells and not their tumorigenic counterparts. Sorafenib in contrast, is highly effective, but not selective. One tested thalidomide derivative has potential as an anti-tumor drug since it induced growth arrest; and importantly, it selectively induced apoptotic cell death only in tumorigenic liver progenitor cells.

dc.publisherElsevier Masson
dc.titleIdentification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib
dc.typeJournal Article
dcterms.source.volume120
dcterms.source.startPage275
dcterms.source.endPage283
dcterms.source.issn0223-5234
dcterms.source.titleEuropean Journal of Medicinal Chemistry
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record